Andrew Holden offers an exclusive first look at the CX 2026 Peripheral Arterial Programme, highlighting the volume of new data being released and discussed.

Peripheral Arterial highlights include:

  • Late-breaking data and 36 podium firsts
  • Further analysis from BASIL-2 and BASIL-3 trials
  • Key new secondary analysis findings from BEST-CLI
  • The SWEDEPAD trial update
  • Pre-recorded live case presentations and discussion